NASDAQ:GILDGilead Sciences Stock Price, Forecast & News

$73.10

-2.06 (-2.74 %)

(As of 06/2/2020 12:42 PM ET)

Add

Compare

Today's Range

$72.96

Now: $73.10▼

$74.64

50-Day Range

$72.34

MA: $77.62▼

$84.00

52-Week Range

$60.89

Now: $73.10▼

$85.97

Volume10.40 million shs

Average Volume12.35 million shs

Market Capitalization$91.69 billion

P/E Ratio18.79

Dividend Yield3.49%

Beta0.68

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Scholar Rock Holding Corporation; Tango Therapeutics; National Cancer Institute; Pfizer, Inc.; Sangamo Therapeutics, Inc.; Gadeta B.V.; HiFiBiO Therapeutics; Agenus Inc.; HOOKIPA Pharma Inc.; Goldfinch Bio, Inc.; and insitro Inc. The company was founded in 1987 and is headquartered in Foster City, California.

Beat the Market (BTM) Rank^™

2.1 Analyst's Opinion

Consensus Rating
Gilead Sciences has received a consensus rating of Hold. The company's average rating score is 2.21, and is based on 9 buy ratings, 16 hold ratings, and 3 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $78.96, Gilead Sciences has a potential upside of 7.9% from its current price of $73.16.
Amount of Analyst Coverage
Gilead Sciences has been the subject of 22 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.3 Community Rank

Outperform Votes
Gilead Sciences has received 2,344 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Gilead Sciences has received 1,209 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Gilead Sciences has received 65.97% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote “Outperform” if you believe GILD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GILD will underperform the S&P 500 over the long term. You may vote once every thirty days.

3.3 Dividend Strength

Dividend Leadership
Gilead Sciences is a leading dividend payer. It pays a dividend yield of 3.49%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Gilead Sciences has only been increasing its dividend for 4 years.
Dividend Coverage
The dividend payout ratio of Gilead Sciences is 44.30 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 41.27 % next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Gilead Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,671,283.00 in company stock.
Percentage Held by Insiders
Only 0.13% of the stock of Gilead Sciences is held by insiders.
Percentage Held by Institutions
80.15% of the stock of Gilead Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Gilead Sciences are expected to grow by 3.13% in the coming year, from $6.39 to $6.59 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Gilead Sciences is 18.81, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.70.
Price to Earnings Ratio vs. Sector
The P/E ratio of Gilead Sciences is 18.81, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.36.
Price to Earnings Growth Ratio
Gilead Sciences has a PEG Ratio of 3.52. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Gilead Sciences has a P/B Ratio of 4.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.20 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:GILD

Previous Symbol

CUSIP37555810

CIK882095

Webwww.gilead.com

Phone650-574-3000

Debt

Debt-to-Equity Ratio1.00

Current Ratio3.04

Quick Ratio2.92

Price-To-Earnings

Trailing P/E Ratio18.79

Forward P/E Ratio11.44

P/E Growth3.52

Sales & Book Value

Annual Sales$22.45 billion

Price / Sales4.08

Cash Flow$6.85 per share

Price / Cash Flow10.67

Book Value$17.90 per share

Price / Book4.08

Profitability

EPS (Most Recent Fiscal Year)$6.14

Net Income$5.39 billion

Net Margins21.84%

Return on Equity35.44%

Return on Assets12.84%

Miscellaneous

Employees11,800

Outstanding Shares1,254,370,000

Market Cap$91.69 billion

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

How has Gilead Sciences' stock been impacted by COVID-19 (Coronavirus)?

Gilead Sciences' stock was trading at $73.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GILD stock has decreased by 0.7% and is now trading at $73.16. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Gilead Sciences?

28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 3 sell ratings, 16 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Gilead Sciences.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Gilead Sciences.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) announced its earnings results on Thursday, April, 30th. The biopharmaceutical company reported $1.68 EPS for the quarter, topping the Zacks' consensus estimate of $1.57 by $0.11. The biopharmaceutical company had revenue of $5.55 billion for the quarter, compared to analyst estimates of $5.44 billion. Gilead Sciences had a return on equity of 35.44% and a net margin of 21.84%. Gilead Sciences's quarterly revenue was up 5.1% compared to the same quarter last year. During the same period last year, the business posted $1.67 earnings per share. View Gilead Sciences' earnings history.

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Thursday, April 30th. Shareholders of record on Friday, June 12th will be paid a dividend of $0.68 per share on Monday, June 29th. This represents a $2.72 annualized dividend and a dividend yield of 3.72%. The ex-dividend date is Thursday, June 11th. View Gilead Sciences' dividend history.

What price target have analysts set for GILD?

28 Wall Street analysts have issued 1 year price targets for Gilead Sciences' stock. Their forecasts range from $60.00 to $90.00. On average, they expect Gilead Sciences' share price to reach $78.96 in the next twelve months. This suggests a possible upside of 7.9% from the stock's current price. View analysts' price targets for Gilead Sciences.

Has Gilead Sciences been receiving favorable news coverage?

Media coverage about GILD stock has been trending very positive on Tuesday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Gilead Sciences earned a media sentiment score of 3.5 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutGilead Sciences.

Are investors shorting Gilead Sciences?

Gilead Sciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 24,110,000 shares, an increase of 6.9% from the April 30th total of 22,550,000 shares. Based on an average trading volume of 24,900,000 shares, the days-to-cover ratio is currently 1.0 days. Currently, 1.9% of the company's stock are sold short. View Gilead Sciences' Current Options Chain.

Who are some of Gilead Sciences' key competitors?

Some companies that are related to Gilead Sciences include Amgen (AMGN), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Immunomedics (IMMU) and Exelixis (EXEL). View all competitors.

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include Walt Disney (DIS), Alibaba Group (BABA), NVIDIA (NVDA), Netflix (NFLX), Intel (INTC), Micron Technology (MU), AbbVie (ABBV), Johnson & Johnson (JNJ), AT&T (T) and Tesla (tsla).

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the following people:

Ms. Robin L. Washington, CFO & Exec. VP (Age 56)
Dr. John G. McHutchison M.D., FRACP, Chief Scientific Officer and Head of R&D (Age 61)
Mr. Gregg H. Alton, Chief Patient Officer (Age 53)
Ms. Laura Hamill, Exec. VP of Worldwide Commercial Operations (Age 54)
Mr. Daniel O'Day, Chairman & CEO (Age 55)

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (8.04%), Capital Research Global Investors (7.65%), State Street Corp (4.53%), Capital International Investors (4.49%), Capital World Investors (3.69%) and Geode Capital Management LLC (1.59%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, John C Martin, John Francis Cogan, Olsen Per Wold and Richard James Whitley. View institutional ownership trends for Gilead Sciences.

Which institutional investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Parnassus Investments CA, BlackRock Inc., Alliancebernstein L.P., Invesco Ltd., Two Sigma Advisers LP, Wellington Management Group LLP, and Franklin Resources Inc.. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, John Francis Cogan, and Olsen Per Wold. View insider buying and selling activity for Gilead Sciences.

Which institutional investors are buying Gilead Sciences stock?

GILD stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Capital World Investors, Capital Research Global Investors, APG Asset Management N.V., Federated Hermes Inc., Perceptive Advisors LLC, Perceptive Advisors LLC, and Prudential PLC. View insider buying and selling activity for Gilead Sciences.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $73.16.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $91.77 billion and generates $22.45 billion in revenue each year. The biopharmaceutical company earns $5.39 billion in net income (profit) each year or $6.14 on an earnings per share basis. Gilead Sciences employs 11,800 workers across the globe.

What is Gilead Sciences' official website?

The official website for Gilead Sciences is www.gilead.com.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff